Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts

During the last three months, 8 analysts shared their evaluations of Taysha Gene Therapies TSHA, revealing diverse outlooks from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.5, a high estimate of $8.00, and a low estimate of $5.00. This current average has increased by 4.0% from the previous average price target of $6.25.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of Taysha Gene Therapies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Taysha Gene Therapies. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Taysha Gene Therapies compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Taysha Gene Therapies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Capture valuable insights into Taysha Gene Therapies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Taysha Gene Therapies analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Taysha Gene Therapies: A Closer Look

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Taysha Gene Therapies: A Financial Overview

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Taysha Gene Therapies's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -62.33%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Taysha Gene Therapies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1427.52% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Taysha Gene Therapies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -25.83% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Taysha Gene Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.41%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.7, caution is advised due to increased financial risk.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.